Merck management commentary: New products drive 5% revenue growth in Q3 2026

Bitget2026/10/29 10:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Merck's management commentary attributed third-quarter 2026 revenue growth of 5% to $18.1 billion to new products, oncology and animal health.
Keytruda-family sales rose 6% excluding currency effects to $8.6 billion, driven by earlier-stage cancer uptake and metastatic demand.
Non-GAAP operating expenses increased 12% to $7.4 billion, reflecting launch investments, pipeline spending and a licensing charge.
Full-year revenue guidance narrowed to $66.8 billion–$67.3 billion; non-GAAP EPS guidance narrowed to $2.77–$2.82, with both midpoints raised.
Favorable U.S. purchase timing boosted quarterly sales by approximately $550 million; Keytruda and Winrevair benefits are expected to reverse in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck management commentary: New products drive 5% revenue growth in Q3 2026

You may also like

Crypto prices